ARN-509: a novel anti-androgen for prostate cancer treatment

Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer (CRPC), the most advanced form of this disease. While established and novel AR-pathway targeting agents display clinical efficacy in metastatic CRPC, dose-limiting side effe...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Clegg, Nicola J., Wongvipat, John, Joseph, Jim, Tran, Chris, Ouk, Samedy, Dilhas, Anna, Chen, Yu, Grillot, Kate, Bischoff, Eric D., Cai, Ling, Aparicio, Anna, Dorow, Steven, Arora, Vivek, Shao, Gang, Qian, Jing, Zhao, Hong, Yang, Guangbin, Cao, Chunyan, Sensintaffar, John, Wasielewska, Teresa, Herbert, Mark R., Bonnefous, Celine, Darimont, Beatrice, Scher, Howard I., Smith-Jones, Peter, Klang, Mark, Smith, Nicholas D., De Stanchina, Elisa, Wu, Nian, Ouerfelli, Ouathek, Rix, Peter J., Heyman, Richard A., Jung, Michael E., Sawyers, Charles L., Hager, Jeffrey H.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2012
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306502/
https://ncbi.nlm.nih.gov/pubmed/22266222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3948
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια